Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (71-80 of 282) with videos related to

Pageof 29
Sort By:
Cancer|April 4, 2003
Overview of bladder cancer trials in the Cancer and Leukemia Group BEric J Small, Susan Halabi, Guido Dalbagni, et al.
Statistics in Medicine|May 19, 2025
Sample Size and Power Calculations With Win Measures Based on Hierarchical EndpointsHuiman Barnhart, Yuliya Lokhnygina, Roland Matsouaka, et al.
Cancer Causes & Control : CCC|December 5, 2002
Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States)Patricia G Moorman, Joellen M Schildkraut, Brian Calingaert, et al.
Endocrine Oncology (Bristol, England)|July 12, 2023
Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancerSean McSweeney, Hannah E Bergom, Anna Prizment, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancerSusan Halabi, Nicholas J Vogelzang, San-San Ou, et al.
Cancer Causes & Control : CCC|September 1, 2005
Anthropometric measurements and epithelial ovarian cancer risk in African-American and White womenCathrine Hoyo, Andrew Berchuck, Susan Halabi, et al.
Cancer|November 8, 2008
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811William Kevin Kelly, Susan Halabi, Aymen Elfiky, et al.
The Prostate|February 26, 2023
Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic scoreMosunmoluwa Oyenuga, Susan Halabi, Abayomi Oyenuga, et al.
Journal of Surgical Oncology|August 3, 2017
Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomesAlyson L Mahar, Carolyn Compton, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2009
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survivalAndrew J Armstrong, Ian F Tannock, Ronald de Wit, et al.
Pageof 29

Showing results (71-80 of 282) with videos related to

Sort By:
Pageof 29
Cancer|April 4, 2003
Overview of bladder cancer trials in the Cancer and Leukemia Group BEric J Small, Susan Halabi, Guido Dalbagni, et al.
Statistics in Medicine|May 19, 2025
Sample Size and Power Calculations With Win Measures Based on Hierarchical EndpointsHuiman Barnhart, Yuliya Lokhnygina, Roland Matsouaka, et al.
Cancer Causes & Control : CCC|December 5, 2002
Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States)Patricia G Moorman, Joellen M Schildkraut, Brian Calingaert, et al.
Endocrine Oncology (Bristol, England)|July 12, 2023
Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancerSean McSweeney, Hannah E Bergom, Anna Prizment, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancerSusan Halabi, Nicholas J Vogelzang, San-San Ou, et al.
Cancer Causes & Control : CCC|September 1, 2005
Anthropometric measurements and epithelial ovarian cancer risk in African-American and White womenCathrine Hoyo, Andrew Berchuck, Susan Halabi, et al.
Cancer|November 8, 2008
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811William Kevin Kelly, Susan Halabi, Aymen Elfiky, et al.
The Prostate|February 26, 2023
Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic scoreMosunmoluwa Oyenuga, Susan Halabi, Abayomi Oyenuga, et al.
Journal of Surgical Oncology|August 3, 2017
Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomesAlyson L Mahar, Carolyn Compton, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2009
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survivalAndrew J Armstrong, Ian F Tannock, Ronald de Wit, et al.
Pageof 29